Drug - Vimizim™ (elosulfase) [BioMarin Pharmaceuticals Inc.]
Therapeutic area - Metabolic disease enzyme replacement
- Patient is 5 years of age or older AND
- Patient has a diagnosis of Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)
- Dosing will be limited to 2 mg/kg/week. Approval will include a quantity sufficient for a 34-day supply. Patient’s weight in kilograms must be supplied at time of prior authorization request and for any subsequent dose increases.
MHCP Provider Call Center 651-431-2700 or 800-366-5411